References of "Bonnet, Christophe"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailResults from the Belgian mantle cell lymphoma registry
Vergote, Vibeke; Janssens, Ann; André, Marc et al

in Acta Clinica Belgica (2017), 38

Introduction: Mantle cell lymphoma is a B-cell non-Hodgkin’s lymphoma characterized by a t(11;14), resulting in overexpression of cyclin D1. Conventional chemotherapy obtains frequent (but short ... [more ▼]

Introduction: Mantle cell lymphoma is a B-cell non-Hodgkin’s lymphoma characterized by a t(11;14), resulting in overexpression of cyclin D1. Conventional chemotherapy obtains frequent (but short) remissions, leading to a poor median overall survival (OS) of 3–5 years. To obtain more information about the prevalence and current treatment of Mantle cell lymphoma (MCL) in Belgium, we collected data in a Belgian registry of MCL. Materials and methods: All Belgian MCL patients, t(11;14) and/or cyclin D1 positive, seen in hematology departments over a one-year period (April 2013–March 2014) were included. Data about patient characteristics, histology, treatment lines, and response were compiled and retrospectively analyzed. Results: Four hundred and four patients were included with a median age at diagnosis of 64 years (range 23–96 years) and a male predominance (72%). For 2013, we calculated a prevalence of at least 36.2 per million and an incidence of at least 7.0 per million in the Belgian population. Characteristics at diagnosis involved lymphadenopathy (82%), splenomegaly (44%), B-symptoms (39%), and hepatomegaly (10%). Bone marrow invasion was present at diagnosis in 77%. Stage at diagnosis was advanced in the majority of cases. The median number of treatment lines was 1. Type of first line treatment included a combination of anthracyclin and cytarabinebased regimen (34%), anthracyclin (39%), and other. Rituximab was used in 88% of first line treatments. In 44% first line treatment was followed by autologous stem cell transplantation. Conclusion: The analysis of this Belgian MCL registry provides insight in the epidemiology, demographics, and current treatment of our Belgian MCL population. [less ▲]

Detailed reference viewed: 9 (0 ULiège)
Full Text
Peer Reviewed
See detailA First Report on [(18)F]FPRGD2 PET/CT Imaging in Multiple Myeloma.
WITHOFS, Nadia ULiege; Cousin, Francois; DE PRIJCK, Bernard ULiege et al

in Contrast Media & Molecular Imaging (2017), 2017

An observational study was set up to assess the feasibility of [(18)F]FPRGD2 PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined ... [more ▼]

An observational study was set up to assess the feasibility of [(18)F]FPRGD2 PET/CT for imaging patients with multiple myeloma (MM) and to compare its detection rate with low dose CT alone and combined [(18)F]NaF/[(18)F]FDG PET/CT images. Four patients (2 newly diagnosed patients and 2 with relapsed MM) were included and underwent whole-body PET/CT after injection of [(18)F]FPRGD2. The obtained images were compared with results of low dose CT and already available results of a combined [(18)F]NaF/[(18)F]FDG PET/CT. In total, 81 focal lesions (FLs) were detected with PET/CT and an underlying bone destruction or fracture was seen in 72 (89%) or 8 (10%) FLs, respectively. Fewer FLs (54%) were detected by [(18)F]FPRGD2 PET/CT compared to low dose CT (98%) or [(18)F]NaF/[(18)F]FDG PET/CT (70%) and all FLs detected with [(18)F]FPRGD2 PET were associated with an underlying bone lesion. In one newly diagnosed patient, more [(18)F]FPRGD2 positive lesions were seen than [(18)F]NaF/[(18)F]FDG positive lesions. This study suggests that [(18)F]FPRGD2 PET/CT might be less useful for the detection of myeloma lesions in patients with advanced disease as all FLs with [(18)F]FPRGD2 uptake were already detected with CT alone. [less ▲]

Detailed reference viewed: 11 (0 ULiège)
Full Text
Peer Reviewed
See detailActivating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell–derived lymphomas
Vallois, David; Dobay, Maria Pamela D.; Morin, Ryan D. et al

in Blood (2016), 128

Angioimmunoblastic T-cell lymphoma (AITL) and other lymphomas derived from follicular T-helper cells (TFH) represent a large proportion of peripheral T-cell lymphomas (PTCLs) with poorly understood ... [more ▼]

Angioimmunoblastic T-cell lymphoma (AITL) and other lymphomas derived from follicular T-helper cells (TFH) represent a large proportion of peripheral T-cell lymphomas (PTCLs) with poorly understood pathogenesis and unfavorable treatment results. We investigated a series of 85 patients with AITL (n 5 72) or other TFH-derived PTCL (n 5 13) by targeted deep sequencing of a gene panel enriched in T-cell receptor (TCR) signaling elements. RHOA mutations were identified in 51 of 85 cases (60%) consisting of the highly recurrent dominant negative G17V variant in most cases and a novel K18N in 3 cases, the latter showing activating properties in in vitro assays. Moreover, half of the patients carried virtually mutually exclusive mutations in other TCR-related genes, most frequently in PLCG1 (14.1%), CD28 (9.4%, exclusively in AITL), PI3K elements (7%), CTNNB1 (6%), and GTF2I (6%). Using in vitro assays in transfected cells, we demonstrated that 9 of 10 PLCG1 and 3 of 3 CARD11 variants induced MALT1 protease activity and increased transcription from NFAT or NF-kB response element reporters, respectively. Collectively, the vast majority of variants in TCR-related genes could be classified as gain-of-function. Accordingly, the samples with mutations in TCR-related genes other than RHOA had transcriptomic profiles enriched in signatures reflecting higher T-cell activation. Although no correlationwithpresenting clinical featuresnor significantimpacton survivalwasobserved, thepresenceofTCR-relatedmutations correlated with early disease progression. Thus, targeting of TCR-related eventsmay hold promise for the treatment of TFH-derived lymphomas. [less ▲]

Detailed reference viewed: 31 (3 ULiège)
Full Text
Peer Reviewed
See detailComparison of combined whole-body 18F-NAF and 18F-FDG PET/CT versus MRI for the detection of myeloma lesions
WITHOFS, Nadia ULiege; COUSIN, François ULiege; TANCREDI, Tino et al

Conference (2016, June 14)

Objectives Imaging requirements for the diagnosis of multiple myeloma (MM) recently changed and 蠅 1 osteolytic bone destruction (蠅 5 mm in size) seen on whole-body (WB) low-dose computed tomography (ldCT ... [more ▼]

Objectives Imaging requirements for the diagnosis of multiple myeloma (MM) recently changed and 蠅 1 osteolytic bone destruction (蠅 5 mm in size) seen on whole-body (WB) low-dose computed tomography (ldCT) or positron emission tomography combined with CT (PET/CT) does fulfill the criteria for bone disease. The present work assessed the lesion detection rate of WB combined [18F]NaF and [18F]FDG PET/CT versus ldCT alone and MRI in patients with newly diagnosed MM. Methods Patients with newly diagnosed MM, prospectively included, underwent WB (from vertex to toes) XR, MRI and combined [18F]NaF and [18F]FDG PET/CT (median delay between scans: 6 days). PET/CT scans were acquired after injection of 134 ± 13 MBq [18F]NaF and 249 ± 18 MBq [18F]FDG (median uptake time: 64 min). The ldCT (3 mm slice thickness; 120 kV; 50-80 mAs) followed by PET emission scan (90 seconds per bed position) were performed. The MR images were acquired in coronal planes in T1-weighted and T2-weighted short-tau inversion recovery. Diffusion-weighted with background suppression images were acquired in the axial plane and reconstructed on coronal planes. PET and LdCT images were reviewed by 2 experienced nuclear medicine physicians and 1 radiologist to detect focal lesions (FLs) and/or diffuse bone marrow involvement. The focal areas of visually detectable increased tracers’ uptake were considered as PET FLs. The MR, ldCT alone and XR images were analyzed by 3 radiologists blinded to each other and to PET/CT results. The FLs were classified according to their location: pelvis, skull, limbs, spine, ribs and one location including the sternum, scapula and clavicles. The McNemar’s test was used to compare the detection rate of each technique and the Kruskal-Wallis test was used to estimate a relationship between the detection rate and the size of FLs measured with ldCT. Results Out of 14 patients initially included, two were excluded (one for a delay > 40 days with XR and one who experienced claustrophobia during MRI acquisition). Twelve myeloma patients (median age 64y) with stage 1 (n = 4), 2 (n = 5) or 3 (n = 3) were included in the analyses. The pattern of bone marrow involvement was focal (n = 7) or combined diffuse and focal (n = 5). Per patient, 1-3 FL (n = 4), 4-10 FLs (n = 2) or > 10 FLs (n = 6) were detected. The total number of FLs detected was 281; no extramedullary disease was detected. The detection rate of MM lesions between techniques was significantly different (p < 0.05): XR (89; 32%) < PET (158; 56%) < MRI (183, 65%) < LdCT alone (219; 78%) < PET/CT (277; 99%). Out of 158 FLs detected with PET, 125 (79%) were also detected with MRI. Out of 183 MM lesions detected with MRI, 125 (68%) were detected with PET; PET positivity was significantly associated with lesion size (p = 0.002). Out of 145 FLs (蠅 5 mm) detected with ldCT, the detection rate of MRI (n = 87; 60%) and PET (n = 96; 66%) was similar (p = 0.17) and significantly associated with lesion size only for MRI (p = 0.014). Whatever FLs location, the detection rate of PET and MRI was similar except for rib MM lesions for which PET was superior to MRI (p = 0.0005). Seventeen osteolytic rib lesions detected with PET were not detected with MRI, of which only one corresponded to a pathologic fracture. At the patient’s level, the diagnosis of MM was based on biological data in 7/12 patients. For the 5 remaining patients, MM diagnosis required imaging. PET/CT and ldCT alone correctly identified bone involvement in all 5 patients; MRI would have missed the correct MM diagnosis in 3 patients (2 with diffuse pattern only and one with 1 FL); WBXR would have missed MM diagnosis in 1/5 patient (one pelvic FL missed). Conclusions The MM lesion detection rate of PET/CT was superior to ldCT alone and MRI, respectively. At the patient’s level, the accuracy of PET/CT and CT alone was superior to MRI and WB-XR for the diagnosis of MM. [less ▲]

Detailed reference viewed: 26 (0 ULiège)
Full Text
Peer Reviewed
See detailBHS guidelines for the treatment of large granular lymphocyte and cronic prolymphocytic leukaemias
Springael, C.; Delrieu, V.; Wu, K.L. et al

in Belgian Journal of Hematology (2016), 7

Large granular lymphocyte and prolymphocytic leukaemias are rare chronic lymphoproliferative disorders. Large granular lymphocyte leukaemias consist of indolent disorders such as T-cell large granular ... [more ▼]

Large granular lymphocyte and prolymphocytic leukaemias are rare chronic lymphoproliferative disorders. Large granular lymphocyte leukaemias consist of indolent disorders such as T-cell large granular lymphocyte and chronic lymphoproliferative disorder of natural killer cells and the very rare but aggressive natural killer cell leukaemia. Treatment of the indolent large granular lymphocyte leukaemias is necessary in case of symptomatic cytopaenias or non-haematological autoimmune disorders. First line therapy of these two disorders is based on three immunosuppressive drugs: methotrexate, cyclophosphamide and cyclosporine A. Aggressive natural killer cell leukaemia needs an L-asparaginase containing regimen as induction followed by allogeneic stem cell transplantation to prolong remission. T-cell prolymphocytic leukaemia always follows an aggressive course even after an indolent onset. The optimal treatment strategy should exist of remission induction with alemtuzumab intravenously followed by autologous or allogeneic stem cell transplantation. Treatment indications for B-cell prolymphocytic leukaemia follow the criteria described by the chronic lymphocytic leukaemia guidelines. After induction with fludarabine, cyclophosphamide, rituximab or bendamustine in patients without a p53 mutation and/or a 17p deletion and alemtuzumab in case of a p53 mutation and/or a 17p deletion, stem cell transplantation must be considered. [less ▲]

Detailed reference viewed: 38 (1 ULiège)
Full Text
Peer Reviewed
See detailPrognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)†
Cottereau, A.S.; Becker, S.; Broussais, F. et al

in Annals of Oncology (2016), 27

Background: Most peripheral T-cell lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed. Patients and methods: The prognostic impact of total ... [more ▼]

Background: Most peripheral T-cell lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed. Patients and methods: The prognostic impact of total metabolic tumor volume (TMTV0), measured on baseline [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography, was evaluated in a retrospective study including 108 PTCL patients (27 PTCL not otherwise specified, 43 angioimmunoblastic T-cell lymphomas and 38 anaplastic large-cell lymphomas). All received anthracycline-based chemotherapy. TMTV0 was computed with the 41% maximum standardized uptake value threshold method and an optimal cut-off point for binary outcomes was determined and compared with others prognostic factors. Results: With a median follow-up of 23 months, 2-year progression-free survival (PFS) was 49% and 2-year overall survival (OS) was 67%. High TMTV0 was significantly associated with a worse prognosis. At 2 years, PFS was 26% in patients with a high TMTV0 (>230 cm3, n = 53) versus 71% for those with a low TMTV0, [P < 0.0001, hazard ratio (HR) = 4], whereas OS was 50% versus 80%, respectively, (P = 0.0005, HR = 3.1). In multivariate analysis, TMTV0 was the only significant independent parameter for both PFS and OS. TMTV0, combined with PIT, discriminated even better than TMTV0 alone, patients with an adverse outcome (TMTV0 >230 cm3 and PIT >1, n = 33,) from those with good prognosis (TMTV0 ≤230 cm3 and PIT ≤1, n = 40): 19% versus 73% 2-year PFS (P < 0.0001) and 43% versus 81% 2-year OS, respectively (P = 0.0002). Thirty-one patients (other TMTV0–PIT combinations) had an intermediate outcome, 50% 2-year PFS and 68% 2-year OS. Conclusion: TMTV0 appears as an independent predictor of PTCL outcome. Combined with PIT, it could identify different risk categories at diagnosis and warrants further validation as a prognostic marker. [less ▲]

Detailed reference viewed: 26 (2 ULiège)
Full Text
Peer Reviewed
See detailPrognostic value of baseline total metabolic tumor volume (TMTVO) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)
Cottereau, A.S.; Becker, S.; Broussais, F. et al

in Annals of Oncology (2016), 27

Background: Most peripheral T-cell lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed. Patients and methods: The prognostic impact of total ... [more ▼]

Background: Most peripheral T-cell lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed. Patients and methods: The prognostic impact of total metabolic tumor volume (TMTV0), measured on baseline [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography, was evaluated in a retrospective study including 108 PTCL patients (27 PTCL not otherwise specified, 43 angioimmunoblastic T-cell lymphomas and 38 anaplastic large-cell lymphomas). All received anthracycline-based chemotherapy. TMTV0 was computed with the 41% maximum standardized uptake value threshold method and an optimal cut-off point for binary outcomes was determined and compared with others prognostic factors. Results: With a median follow-up of 23 months, 2-year progression-free survival (PFS) was 49% and 2-year overall survival (OS) was 67%. High TMTV0 was significantly associated with a worse prognosis. At 2 years, PFS was 26%in patients with a high TMTV0 (>230 cm3, n = 53) versus 71% for those with a low TMTV0, [P < 0.0001, hazard ratio (HR) = 4], whereas OS was 50% versus 80%, respectively, (P = 0.0005, HR = 3.1). Inmultivariate analysis, TMTV0 was the only significant independent parameter for both PFS and OS. TMTV0, combined with PIT, discriminated even better than TMTV0 alone, patients with an adverse outcome (TMTV0 >230 cm3 and PIT >1, n = 33,) from those with good prognosis (TMTV0 ≤230 cm3 and PIT ≤1, n = 40): 19% versus 73% 2-year PFS (P < 0.0001) and 43% versus 81% 2-year OS, respectively (P = 0.0002). Thirty-one patients (other TMTV0–PIT combinations) had an intermediate outcome, 50% 2-year PFS and 68%2-year OS. Conclusion: TMTV0 appears as an independent predictor of PTCL outcome. Combined with PIT, it could identify different risk categories at diagnosis and warrants further validation as a prognostic marker. [less ▲]

Detailed reference viewed: 5 (0 ULiège)
Full Text
Peer Reviewed
See detailPrimary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies
Pilorge, Sylvain; Harel, Stephanie; Ribrag, Vincent et al

in Leukemia & Lymphoma (2016), 57

Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare DLBCL location variant. We treated 76 PB-DLBCL patients by immuno-chemotherapy, resulting in an 84% sustained complete remission rate and a ... [more ▼]

Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare DLBCL location variant. We treated 76 PB-DLBCL patients by immuno-chemotherapy, resulting in an 84% sustained complete remission rate and a 78.9% survival over a 4.7-year median follow-up period. Ann Arbor stage IV and high age-adjusted international prognostic index were predictive of adverse outcome in univariate analysis. In multivariate analysis using a Cox model, only aa-IPI predicted long-term survival. While based on a limited number of cases, we suggested that radiotherapy may be useful as a consolidation modality in PB-DLBCL. We also suggested that positron emission tomography/CT scan should be interpreted with caution due to a persistent [18F]fluorodeoxyglucose [18FDG] uptake of bone lesions even after remission in some in PB-DLBCL patients. Our study based on a homogeneous cohort of PB-DLBCL patients confirmed the favorable outcome of this DLBCL variant and support the implementation of prospective clinical trials in this disease. [less ▲]

Detailed reference viewed: 7 (0 ULiège)
Full Text
Peer Reviewed
See detailHighlights of the 13th International Conference on Malignant Lymphoma
BONNET, Christophe ULiege; BOSLY, A.

in Belgian Journal of Hematology (2015), 6(4), 173-178

A lot of interesting data were presented at the 13th International Conference on Malignant Lymphoma in Lugano, Switzerland. The authors summarise below those presentations/abstracts they found relevant ... [more ▼]

A lot of interesting data were presented at the 13th International Conference on Malignant Lymphoma in Lugano, Switzerland. The authors summarise below those presentations/abstracts they found relevant for daily practice, either now or in the near future. [less ▲]

Detailed reference viewed: 57 (0 ULiège)
Full Text
Peer Reviewed
See detailWaldenström's macroglobulinaemia: Belgian Hematology Society guidelines
VAN HENDE, V.; BRON, D.; VAN DEN NESTE, E. et al

in Belgian Journal of Hematology (2015), 6(4), 142-151

Waldenström’s macroglobulinaemia is a B-cell disorder characterised by bone marrow infiltration with lymphoplasmacytic cells, along with demonstration of an IgM monoclonal gammopathy in the blood. This ... [more ▼]

Waldenström’s macroglobulinaemia is a B-cell disorder characterised by bone marrow infiltration with lymphoplasmacytic cells, along with demonstration of an IgM monoclonal gammopathy in the blood. This condition belongs to the lymphoplasmacytic lymphomas as defined by the World Health Organization classification (ICD-0 code 9671/3). Approximately one-fourth of patients are asymptomatic. Clinical features of the symptomatic patients are diverse and may relate to overall disease burden (such as peripheral blood cytopaenias, organomegaly and constitutional symptoms) or may be directly attributable to the IgM paraprotein. The latter include hyperviscosity syndrome, amyloidosis, peripheral neuropathy and cold haemagglutinin. Therapeutic options have traditionally involved alkylating agents, nucleoside analogues, and rituximab, either as single therapy or in combination. However, emerging new data on combination therapy as well as novel agents have shown encouraging results. This report provides the Belgian Hematology Society guidelines according to recent clinical studies. [less ▲]

Detailed reference viewed: 43 (0 ULiège)
Full Text
Peer Reviewed
See detailErythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival
JASPERS, Aurélie ULiege; Baron, Frédéric ULiege; SERVAIS, Sophie ULiege et al

in American Journal of Hematology (2015), 90(9), 197-199

Detailed reference viewed: 36 (9 ULiège)
Full Text
Peer Reviewed
See detailLong-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.
JASPERS, Aurélie ULiege; Baron, Frédéric ULiege; Maertens, Johan et al

in American Journal of Hematology (2015), 90(7), 133-4

Detailed reference viewed: 33 (7 ULiège)
Full Text
See detailPrise en charge actuelle du lymphome de la zone marginale
Bonnet, Christophe ULiege; LEJEUNE, Marie ULiege; VAN KEMSEKE, Catherine ULiege et al

in Revue Médicale Suisse (2015), 11

Detailed reference viewed: 46 (6 ULiège)
Full Text
Peer Reviewed
See detailBHS guidelines for the treatment of Burkitt lymphoma
BONNET, Christophe ULiege; Janssens, A.; Wu, KL. et al

in Belgian Journal of Hematology (2015), 6(2), 61-69

Burkitt lymphoma (BL) is a rare but very aggressive non-Hodgkin’s lymphoma characterized by an isolated translocation t(8;14)(q24;q32). The sporadic form is the subentity most frequently encountered in ... [more ▼]

Burkitt lymphoma (BL) is a rare but very aggressive non-Hodgkin’s lymphoma characterized by an isolated translocation t(8;14)(q24;q32). The sporadic form is the subentity most frequently encountered in our country. Diagnosis and initial work-up must be completed rapidly to start treatment as soon as possible. Positron emission tomography (PET) scan is useful for initial staging and to evaluate the chemosensitivity of the tumor during and after treatment. After debulking, it is recommended to add rituximab to chemotherapy. Currently intensive short-cycle chemotherapies (ISCC) and low intensity chemotherapies (LIC) are two valuable options. Radiotherapy is not indicated except in case of central nervous system involvement. Patients achieving complete remission must be followed carefully during the first year to detect recurrence of the disease. More than 80% of patients sustain their remission one year following initial treatment and are considered cured. For patients in partial remission or with chemosensitive relapse, autologous stem cell transplantation is recommended following re-induction with non-cross-resistant polychemotherapy. Monitoring complete blood counts and cognitive functions is important to detect late toxicity of the applied therapies. [less ▲]

Detailed reference viewed: 124 (15 ULiège)
Full Text
Peer Reviewed
See detailHaemolytic crisis induced by rasburicase administration revealing G-6-PD deficiency
SID, Sélim ULiege; Dugauquier, Christophe; DE PRIJCK, Bernard ULiege et al

in Belgian Journal of Hematology (2015), 6(2), 74-78

We present a patient with Burkitt's lymphoma who suffered a severe haemolytic crisis after treatment with rasburicase. This case report underlines the high incidence of glucose-6-phosphate dehydrogenase ... [more ▼]

We present a patient with Burkitt's lymphoma who suffered a severe haemolytic crisis after treatment with rasburicase. This case report underlines the high incidence of glucose-6-phosphate dehydrogenase deficiency in some ethnic groups and the importance of a detailed patient and family history before starting treatment, even in case of emergency. Glucose-6-phosphate dehydrogenase is an essential enzyme since it makes the synthesis of NADPH + H from NADP possible, which determines the reducing power (NADPH) of the cell. Every defect in this physiological process, notably glucose-6-phosphate dehydrogenase deficiency, may thus result simultaneously with the use of rasburicase in acute or chronic haemolysis according to the importance of the deficiency. Management is based on stopping the incriminated drug and on supportive therapy consisting of administering packed red blood cells if the anaemia is poorly tolerated. [less ▲]

Detailed reference viewed: 22 (4 ULiège)
Full Text
Peer Reviewed
See detailSputum cytokines levels in patients undergoing hematopoietic SCT (HSCT) and comparison with healthy subjects and COPD: a pilot study
MOERMANS, Catherine ULiege; BONNET, Christophe ULiege; WILLEMS, Evelyne ULiege et al

in Bone Marrow Transplantation (2014), 49(11), 1382-1388

Patients undergoing hematopoietic stem cell transplantation (HSCT) display an airway neutrophilic inflammation before the transplantation that persists over the years. In this study, we have investigated ... [more ▼]

Patients undergoing hematopoietic stem cell transplantation (HSCT) display an airway neutrophilic inflammation before the transplantation that persists over the years. In this study, we have investigated the cytokine profile over a period of one year in sputum supernatant of patients who underwent HSCT. We have measured sputum supernatant levels of TNF-α, TGF-β1, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17, and IFN-γ in 49 HSCT patients and compared the results with those found in 40 COPD and 54 healthy subjects matched for age. Compared to healthy subjects, before the transplantation, HSCT patients exhibited raised levels of IL-6 (p<0.001) and IL-8 (p<0.05) while the other cytokines were generally poorly detectable. This picture was rather similar to what is seen in COPD even if cytokine levels were much greater in the latter with IL-8 being significantly greater in COPD than in HSCT patients (p<0.0001). In the 1 year following the transplantation, sputum IL-6 and IL-8 did not differ any longer compared to healthy subjects. Overall in HSCT patients, sputum IL-8 and IL-6 correlated with sputum neutrophil counts (r=0.4, p<0.0001; r=0.42, p<0.0001, respectively). In conclusion, sputum IL-6 and IL-8 may play a role in neutrophilic airway inflammation seen in patients undergoing HSCT. [less ▲]

Detailed reference viewed: 61 (21 ULiège)
Full Text
Peer Reviewed
See detailTreatment of mantle cell lymphomas: recommendations of the Belgian Hematological Society
MOURIN, E.; VAN HOOF, A.; BOSLY, A. et al

in Belgian Journal of Hematology (2014), 5

Mantle cell lymphoma was recognised in the nineties and is characterised by the t(11;14)(q13;q32) translocation which results in overexpression of cyclin D1.1 This disease represents approximately 6% of ... [more ▼]

Mantle cell lymphoma was recognised in the nineties and is characterised by the t(11;14)(q13;q32) translocation which results in overexpression of cyclin D1.1 This disease represents approximately 6% of all non-Hodgkin's lymphomas. Mantle cell lymphoma generally affects patients over 60 years-old. Most patients have advanced disease (>70 % Ann Arbor stage IV). Several efforts have been made to predict outcome in mantle cell lymphoma. The cell-proliferation marker Ki-67, the Mantle Cell Lymphoma International Prognostic Index, fluorodeoxyglucose positron emission tomography and minimal residual disease are prognostic tools. For young patients, chemoimmunotherapy followed by high-dose chemotherapy plus stem cell transplantation is the treatment of choice. For the main group of older patients, chemo-immunotherapy followed by maintenance with rituximab is the gold standard. In relapses, temsirolimus is actually registered and new drugs, such as ibrutinib, are currently evaluated with promising preliminary results.2 [less ▲]

Detailed reference viewed: 55 (1 ULiège)
Full Text
Peer Reviewed
See detailBHS guidelines for the treatment of marginal zone lymphomas.
BRON, D.; VAN DEN NESTE, E.; KENTOS, A. et al

in Belgian Journal of Hematology (2014), 5

Marginal zone lymphomas are a heterogeneous subtype of indolent B-non-Hodgkin Lymphoma that includes three distinct diseases: Extranodal mucosa associated lymphoid tissue lymphoma, nodal marginal zone ... [more ▼]

Marginal zone lymphomas are a heterogeneous subtype of indolent B-non-Hodgkin Lymphoma that includes three distinct diseases: Extranodal mucosa associated lymphoid tissue lymphoma, nodal marginal zone lymphoma and splenic marginal zone lymphoma lymphocytes +/- villous lymphocytes. The different diagnosis, work up and treatment options are discussed in these guidelines. [less ▲]

Detailed reference viewed: 77 (0 ULiège)